Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Sarchi also recently made the following trade(s):
- On Thursday, April 2nd, Christopher Sarchi sold 6,500 shares of Replimune Group stock. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00.
Replimune Group Stock Performance
REPL opened at $9.47 on Friday. The firm has a market cap of $781.94 million, a P/E ratio of -2.75 and a beta of 0.91. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $13.24. The company has a 50 day simple moving average of $5.11 and a two-hundred day simple moving average of $7.28. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.
Analyst Ratings Changes
Read Our Latest Stock Report on REPL
Institutional Trading of Replimune Group
A number of institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP bought a new stake in shares of Replimune Group in the 1st quarter valued at about $921,000. Essential Partners LLC raised its position in Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the last quarter. Bank of America Corp DE raised its position in Replimune Group by 17.7% during the 1st quarter. Bank of America Corp DE now owns 253,449 shares of the company’s stock worth $1,939,000 after buying an additional 38,119 shares during the last quarter. Readystate Asset Management LP purchased a new position in shares of Replimune Group during the 1st quarter valued at approximately $1,059,000. Finally, EcoR1 Capital LLC purchased a new position in shares of Replimune Group during the 1st quarter valued at approximately $7,650,000. 92.53% of the stock is currently owned by institutional investors.
About Replimune Group
Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.
Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.
Featured Stories
- Five stocks we like better than Replimune Group
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
